Tonix Pharmaceuticals Pioneering in the shifting landscape of the Dynamic CNS Therapeutics Market
Globe PR Wire 13-Feb-2024 4:50 AM
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a leading American biotech company, is spearheading a paradigm shift in the landscape of biotech stocks through its groundbreaking advancements in Central Nervous System (CNS) therapeutics.
The prevalence of CNS disorders, affecting at least 26% of American adults according to a study by Johns Hopkins Medicine, underscores the urgent need for effective treatments. However, the daunting complexity of CNS drug discovery has historically hindered progress, with low success rates and staggering resource requirements.
Peering into the CNS Market
The CNS therapeutics market, valued at USD 104.70 billion in 2023, is projected to reach USD 159.84 billion by 2030, driven by increasing demand for effective treatments across a spectrum of disorders. Key segments include neurovascular diseases, trauma, mental health conditions, degenerative diseases, infectious diseases, and cancer.
Prominent players in this industry consist of the following:
- Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)
Acadia Pharmaceuticals Inc. is a biopharmaceutical company based in San Diego, California. It is known for developing drugs for central nervous system disorders, with a notable product being Nuplazid, a drug designed to stimulate a subset of the brain's serotonin receptors.
- NRX Pharmaceuticals (NASDAQ:NRXP)
NRX Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing therapeutics for central nervous system disorders, specifically suicidal depression, and post-traumatic stress disorder (PTSD).
- Sangamo Therapeutics (NASDAQ:SGMO)
Sangamo is a genomic medicine company that uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from diseases for which today's medicine can only offer symptom management at best.
Introducing Tonix Pharmaceuticals
Tonix Pharmaceuticals' (NASDAQ:TNXP) lead CNS candidate, TNX-102 SL for Fibromyalgia, has completed two positive Phase 3 studies, with plans for a New Drug Application (NDA) filing in the second half of 2024. Additionally, TNX-1300 for Cocaine Intoxication/Overdose has received Breakthrough Therapy Designation, while TNX-1500 for Organ Transplant Rejection/Autoimmune Disorders is enrolling for Phase I. TNX-2900 for Prader-Willi Syndrome has completed the clinical phase of its Phase 2 study.
Targeting a Wide Total Addressable Market
Tonix's offerings strategically target a diverse range of CNS conditions, including Fibromyalgia, Cocaine Intoxication/Overdose, Organ Transplant Rejection/Autoimmune Disorders, Major Depressive Disorder, and Acute Migraine, catering to millions worldwide.
These figures underscore the vast potential of Tonix's offerings in addressing a wide total addressable market in the CNS space. Because Tonix is still a micro-player with a market capitalization of less than $20 million, its growth runway seems phenomenal, at this stage.
Strategic, Value-Adding Partnerships
Tonix Pharmaceuticals (NASDAQ:TNXP) has forged strategic partnerships with government institutions, academic research organizations, and biotech companies, enhancing its research capabilities and expanding its product portfolio.
Assessing Stock Potential
Despite trading near its 52-week low, TNXP demonstrates resilience with a modest uptick in recent months and promising EPS growth projections, signaling potential for significant upswing in the near future. Analysts rate this pick as a buy.
Tonix Pharmaceuticals' (NASDAQ:TNXP) innovative research, successful clinical trials, and strategic partnerships position the company for success in the dynamic CNS therapeutics market. With a commitment to transforming the lives of millions affected by CNS disorders, Tonix Pharmaceuticals continues to lead the charge toward a brighter future in neurological healthcare.
Read full More About TNXP: https://www.stockstelegraph.com/tnxp
Sources:
https://link.springer.com/article/10.1007/s00213-021-05838-3
https://www.gminsights.com/industry-analysis/central-nervous-system-therapeutics-market
https://www.cdc.gov/arthritis/types/fibromyalgia.htm
https://www.samhsa.gov/data/sites/default/files/reports/rpt29393/2019NSDUHFFRPDFWHTML/2019NSDUHFFR090120.htm
https://www.businesswire.com/news/home/20170717005452/en/Global-50-Billion-Transplantation-Market-Analysis-Forecasts-2014-2025-By-Product-Application-End-use-And-Segment-Forecasts---Research-and-Markets
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241552/
Disclaimer: This report is for information purposes only and is neither a solicitation or recommendation to buy nor an offer to sell securities. Million News Media Inc. is not-a-registered-investment-advisor. Million News Media Inc. is not a broker-dealer. Information, opinions, and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Million News Media Inc., its wholly owned subsidiaries, websites and social media platforms, youtube channel (@stockstelegraph) accepts no liability for any losses arising from an investor's reliance on the use of this material. Starting on February 12, 2024 till February 16, 2024, Million News Media Inc. has been compensated $23,000 (for one week) for coverage of Tonix Pharmaceuticals (TNXP) by Botanitom Corporation. Million News Media Inc. and its affiliates or officers may purchase, hold, and sell shares of common stock of this stock, in the open market at any time without notice. Million News Media Inc. will not update its purchases and sales of this stock in any future postings on Million News Media Websites and social media channels including its own and other forums they may post. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," "project," and similar expressions and variations thereof are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Million News Media Inc. does not set price targets on securities. Never invest in a stock discussed on this website or in this email alert unless you can afford to lose your entire investment.
